jhli98

Metastatic pancreatic cancer treatment is increasingly personalized, considering tumor biology, patient health, and treatment goals. Assessing comorbidities, nutrition, and performance status helps guide therapy intensity, while molecular testing—including BRCA and RAS mutations—identifies actionable targets. The FDA-approved NALIRIFOX regimen (liposomal irinotecan, oxaliplatin, 5-FU, leucovorin) demonstrated improved outcomes over gemcitabine plus nab-paclitaxel in the NAPOLI 3 trial. Compared […]

Neladalkib (NVL-655) has shown strong results in patients with ALK-positive solid tumors, according to new data from the phase 1/2 ALKOVE-1 study. The drug achieved a 44% overall response rate among 34 patients, including 69% in those who had never received an ALK inhibitor and 29% in those previously treated with one. Responses appeared quickly,

A new study from University of Chicago, published in Cell Reports Medicine, suggests that zeaxanthin, a plant carotenoid known for eye health, may also boost the immune system’s ability to fight cancer. The compound enhances CD8+ T cells, the body’s tumor-killing immune cells, by stabilizing their T-cell receptor (TCR) complex, leading to stronger activation and